This page has beta status

MPNS COST Action MP1404
Simulation and pharmaceutical technologies for advanced patient-tailored inhaled medicines (SimInhale)

As a result of the culmination of several scientific and technological developments, we are on the verge of technological breakthroughs in the field of inhaled medicines that will revolutionize the treatment of many acute or chronic respiratory and systemic illnesses. However, knowledge in the field is vertically fragmented and compartmentalized in disciplines. As a result, current developments are not necessarily synergistic and supportive of each other. The prospect of patient-tailored inhaled medicines necessitates a much closer coordination of research and development activities. Simlnhale aims to create a pan-European network of experts in order to: i) advance particle designs for improved deposition and interaction with lung tissue, ii) promote realistic computer simulations of particle aerosolization, delivery and deposition, iii) promote patient-tailored inhaled medicines, iv) promote integration of device and formulation design, and v) promote critical assessment of toxicity issues and related risks. Making a new generation of advanced inhaled pharmaceuticals available to patients in a shorter period of time will have enormous social benefits.

(Descriptions are provided by the Actions directly via e-COST.)

General Information*

Chair of the Action:

Prof Stavros KASSINOS (CY)

Vice Chair of the Action:

Prof Gerrit BORCHARD (CH)

Science officer of the Action:

Dr Federica ORTELLI

Administrative officer of the Action:

Ms Jeannette NCHUNG ORU


Action Fact Sheet

Download AFS as .RTF

Memorandum of Understanding

Download MoU as PDF

Second Progress Report

Download Second Progress Report as PDF


* content provided by e-COST.
Data is synchronised once per night.


Last updated: 19 November 2014 top of page